Peter L. Hoang has been appointed president and chief executive officer, TapImmune, Inc. Dr. Glynn Wilson, who was recently re-appointed as chairman, will now serve in a new role as the company’s Strategic Advisor.
 
Mr. Hoang has more than 20 years of investment banking, venture capital, immuno-oncology and public company executive management experience. Most recently he served as senior vice president of business development and Strategy at Bellicum Pharmaceuticals. He also served as managing director of Innovations at The University of Texas MD Anderson Cancer Center, and headed the new venture formation and development effort for the institution. Before joining MD Anderson, Mr. Hoang was a senior investment banker, most recently as managing director and head of healthcare mergers & acquisitions advisory for CIT Group.
 
“We are delighted to welcome Peter as our new CEO, as we focus on taking TapImmune into new frontiers as a leading biopharmaceutical organization,” said Dr. Glynn Wilson, chairman of the board of directors. “Peter joins us with an extraordinary background that combines capital markets, oncology, and executive management experience. We are confident that his ability and vision will lead us through the next phases of our clinical and corporate development and will enhance the value of the Company. Peter is an experienced leader and executive with proven skills in finance, operational execution, and business development, and he has the unanimous support of the Board to lead TapImmune through its clinical trials and product development.”